

## IN THE CLAIMS

1. (Withdrawn).
2. (Withdrawn).
3. (Withdrawn).
4. (Withdrawn).
5. (Currently Amended). An hepatocyte-specific target delivery molecule [produced by the process of claim 1] comprising a synthesized water insoluble target molecule complex comprising a bridging agent selected from the group consisting of a transition element, an inner transition element, a neighbor element of said transition element and a mixture of any of the foregoing elements; and a complexing agent; provided that when said transition element is chromium, a chromium target molecule complex is created; in combination with a liposome matrix.
6. (Withdrawn).
7. (Currently Amended). [A] The hepatocyte-specific target delivery molecule of claim 5 [produced by the process of claim 6] wherein a pharmacological, therapeutic, or diagnostic agent is combined with said target delivery molecule to form an hepatocyte-specific targeted delivery system.
8. (Currently Amended). The hepatocyte-specific targeted delivery system [The target delivery molecule] of claim 7, wherein said pharmacological, therapeutic, or diagnostic agent is [encompassed] sequestered by the liposome matrix or entrapped in the liposome core volume or associated with the liposome surface or is otherwise captured by the liposome through the utilization of combinations of these sequestering means.
9. (Currently Amended). The hepatocyte-specific targeted delivery system [The target delivery molecules] of claim 7, wherein said pharmacological agent comprises insulin or a derivative thereof.
10. (Currently Amended). The hepatocyte-specific targeted delivery system [The target delivery molecule] of claim 7, wherein said pharmacological agent comprises serotonin or a serotonergic agent.
11. (Currently Amended). The hepatocyte-specific targeted delivery system [The target delivery molecule] of claim 7, wherein said liposome [liposome matrix] comprises distearoyl lecithin, cholesterol, and dicetyl phosphate.
12. (Currently Amended). The hepatocyte-specific targeted delivery system [The target delivery molecules of claim 11] of claim 7, wherein said pharmacological agent is selected from insulin, a derivative of insulin, and serotonin.

13. (Currently Amended). An hepatocyte-specific targeting molecule, comprising  
(a) a liposomal membrane; and  
(b) a target complex comprising (a') a bridging element or a dissociated moiety [of] thereof or a water insoluble polynuclear complex or a mixture of the foregoing, where said dissociated moiety exists with or without metal in the liposome membrane; and (b') a complexing agent; provided that when said bridging element is chromium a chromium target molecule complex as shown in Figure 2 is present in the hepatocyte targeting molecule.
14. (Currently Amended). The hepatocyte-specific targeting molecule of claim 13 wherein said complexing agent comprises N-(2,6-diisopropylphenylcarbamoylmethyl)iminodiacetic acid.
15. (Currently Amended). The hepatocyte-specific targeting molecule of claim 13 wherein said liposome membrane comprises a lipid selected from distearoyl lecithin, cholesterol, dicetyl phosphate and a mixture of the foregoing lipids.
16. (Currently Amended). The hepatocyte-specific targeting molecule of claim 15 wherein said liposome membrane comprises a mixture of distearoyl lecithin, cholesterol, and dicetyl phosphate.
17. (Currently Amended). The hepatocyte-specific targeting molecule of claim 16 wherein said distearoyl lecithin is present in an amount of about 25.5 micro moles/ml, said cholesterol is present in an amount of about 6.85 micro moles/ml and said dicetyl phosphate is present in an amount of about 9.4 micro moles/ml with 0.465 micro moles/ml of chromium complex.
18. (Original). An article of manufacture for delivering an agent in liposome form to the hepatocytes in the liver containing first member comprising a chromium target molecule complex or a dissociated moiety thereof, said first member being soluble in a second member comprising a liposome which is capable of carrying the agent, wherein said first member is specific for cellular hepatocytes, exhibits a maximum visible absorption spectrum at 5250 Angstroms, is soluble in organic solvents and has a first structural component which is chromium and a second and a third structural component comprising at least one complexing agent or a mixture of complexing agents.
19. (Original). The article of manufacture of claim 18 wherein said complexing agent comprises N-(2,6-diisopropylphenylcarbamoylmethyl)iminodiacetic acid.
20. (Original). The article of manufacture of claim 18 wherein the agent comprises a therapeutic agent.
21. (Original). The article of manufacture of claim 18 wherein the agent comprises a diagnostic agent.
22. (Original). A liposome delivery system directed to hepatocytes of a warm-blooded host comprising a liposome, at least one bridging agent complex which is insoluble in water and soluble in said liposome and an active agent destined to be delivered to the hepatocytes which is carried by said liposome.
23. (Original). The system of claim 22 wherein said active agent is a therapeutic agent.
24. (Original). The system of claim 22 wherein said active agent is a diagnostic agent.

25. (Original). The system of claim 22 wherein said bridging agent complex comprises a chromium target molecule complex or a dissociated form thereof.
26. (Original). The system of claim 25 wherein said chromium target molecule complex is complexed with N-(2,6-diisopropylphenylcarbamoylmethyl)iminodiacetic acid.
27. (Original). The system of claim 22 wherein said active agent is insulin or a derivative thereof.
28. (Original). The system of claim 22, wherein said active agent comprises an insulin derivative, said derivative being composed of a single or several combinations of monomeric insulin subunits ranging in composition from one monomeric subunit to nine associated monomeric subunits or a combination thereof, wherein at least one of said derivatives preferentially loads into the core or into the membrane or onto the surface of said liposome for delivery to the hepatocytes in the liver of a warm-blooded host.
29. (Withdrawn).
30. (Cancelled).
31. (Withdrawn).
32. (Currently Amended). A composition for delivering an active agent to a target site in a mammal which comprises, a transport agent comprising a liposome having associated therewith a bridging agent selected from a metal complex, a dissociated form thereof or a water insoluble polynuclear complex or a mixture of any of the foregoing; where said dissociated form exists with or without metal present in said liposome; provided that when compound chromium is used, it is present as a chromium target molecule complex or a dissociated form thereof.
33. (Original). The composition as defined in claim 32 wherein said liposome comprises a lipid selected from distearoyl lecithin, cholesterol, dicetylphosphate and a mixture of any of the foregoing lipids.
34. (Currently Amended). The composition as defined in claim 32 [33] wherein said liposome comprises a mixture of distearoyl lecithin, cholesterol, and dicetyl phosphate.
35. (Original). The composition as defined in claim 32 which further comprises an active agent associated with said liposome.
36. (Original). The composition as defined in claim 35 wherein said active agent is selected from insulin, a derivative thereof, or serotonin.
37. through 41. (Withdrawn).

42. (New). An hepatocyte-specific targeted delivery system which is a water-insoluble, crystalline polymeric complex of exceptionally high-molecular weight incorporated into a liposome carrier system which directs the targeted delivery of an encapsulated pharmacological, diagnostic, or therapeutic agent to the hepatocytes in the liver of a warm-blooded host, the polymeric complex comprising:
- (a) multiple copies of the transition series element chromium; and
  - (b) multiple copies of a bio-organic moiety capable of individually complexing said transition series element, wherein a greatly polymerized structure containing multiple octahedral subunits is formed and said polymer contains many atoms of chromium and extended multiples of two bio-organic moieties that result in the formation of an exceptionally high-molecular weight polymerized (bis)chromium complex, which is represented by a prolonged repeating octahedral structure thereby creating the high-molecular weight polymeric derivative.
43. (New). The hepatocyte-specific targeted delivery system of claim 42, wherein said pharmacological agent comprises insulin or a derivative thereof.
44. (New). The hepatocyte-specific targeted delivery system of claim 42, wherein said pharmacological agent comprises serotonin or a serotoninergic agent.
45. (New). The hepatocyte-specific targeted delivery system of claim 42, wherein said pharmacological agent is selected from insulin, a derivative of insulin, and serotonin.
46. (New). The hepatocyte-specific targeted delivery system of claim 42, wherein the liposome of said carrier system comprises a lipid selected from distearoyl lecithin, cholesterol, dicetylphosphate, and a mixture of any of the foregoing lipids.
47. (New). The hepatocyte-specific targeted delivery system of claim 42, wherein said polymeric complex polymerizes and exhibits a crystalline structure at a pH between 3.2 and 3.3.
48. (New). The polymeric complex of exceptionally high-molecular weight of claim 42, wherein the water solubility of said complex is negated while organic solvent solubility of said complex is promoted and enhanced permitting the incorporation of said polymeric complex into selected lipid constructs for the purpose of making the hepatocyte-specific targeted delivery system commercially feasible.